Fig. 7: Decision-making workflow for selecting treatment for newly diagnosed ER+/HER2- metastatic breast cancer patients. | npj Precision Oncology

Fig. 7: Decision-making workflow for selecting treatment for newly diagnosed ER+/HER2- metastatic breast cancer patients.

From: AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

Fig. 7: Decision-making workflow for selecting treatment for newly diagnosed ER+/HER2- metastatic breast cancer patients.

Phosphoproteomic-based quantification of PI3K/AKT/mTOR activity in tumor samples using the LCM/RPPA workflow allows to identify patients with high pathway activation that may benefit from the addition of a PI3K inhibitor to sensitize resistant tumors to ET in combination with CDK4/6 inhibition.

Back to article page